While Porinju Veliyath has confidently asserted that his favourite Pharma stock can give up to 100% gains in 2 years, Daljeet Kohli is cautious and has recommended a sell. Both stalwarts have given cogent reasons in support of their respective stands. Which one will be proved right?
Porinju Veliyath has the luck of the devil. A mid-cap Pharma stock that he declared as a ‘high conviction’ pick has surged and filled his pockets with gold. Porinju claims that more gains are due from the stock. He has also put the spotlight on new stock picks
Spark Capital has identified several top-quality mid-cap stocks which have potential for gains and are investment worthy
Daljeet Kohli is known to be a master of Pharma stocks while Porinju Veliyath is lauded for his expertise in harvesting mega gains from underdog stocks. Both have homed in on a mid-cap Pharma stock but expressed contrary views about its future prospects
Today, when panic-stricken investors were running helter-skelter due to NAMO’s knee-jerk crackdown over their favourite stocks, the Gurus had a benign smile. Their immense wisdom had spared them once again from calamity & carnage!
Amar Ambani of IIFL has evaluated the Q3FY16 performance of several stocks and given buy/ sell recommendations with price targets
Top brass managements usually keep a stiff upper lip when confronted with negative reports of analysts about their companies. However, Kiran Mazumdar Shaw of Biocon has adopted a combative stance and is proactively trashing the negative reports as being “illogical” and based on “poor understanding” while lauding the ones that are favourable to the Company
Four ace stock pickers, each with a proven track record for finding winning stocks, have put their heads together to identify 16 top-quality stocks that are destined to give multibagger gains in the year 2016 and beyond
Daljeet Kohli of IndiaNivesh has revealed his favourite stocks in interviews to ETNow & Business Standard
Daljeet Kohli and his team at IndiaNivesh have conducted a comprehensive preview of the Q2FY15E Results of the best pharma stocks and given buy/ hold recommendations
Recent Comments